OSE Immunotherapeutics: Leadership to Meet with Investors
OSE Immunotherapeutics announces its participation in two investor conferences scheduled for spring 2026. The management will present the company and meet with wealth managers, financial advisors, and investors.
OSE Immunotherapeutics will attend the 'Mardi de la Bourse - Lyon Pôle Bourse' on April 7, 2026, in Lyon, and the 14th Degroof Petercam Healthcare Conference on May 6, 2026, which will be held in a virtual format. Marc Le Bozec, CEO, will lead the presentations at both events and will be joined by Thomas Gidoin, CFO, for Q&A sessions and meetings with investors.
Engaging with a Diverse Investor Base
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
At the Lyon forum, the company will meet with wealth managers, financial advisors, and individual investors. During the Degroof Petercam conference, discussions will primarily involve the professional investor community.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Risks mentioned
Taux de trésorerie et équivalents de trésorerie de 17,0 millions d'euros au 31 mars 2026 en baisse.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
